Protease inhibitor for use in combination with other antiretroviral agents for the treatment of HIV. Generic name for Lexiva®.

Fosamprenavir (marketed by Glaxo Smith Kline as fosamprenavir calcium, under the trade name Lexiva®) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient.